Sarcoma  >>  RG4733  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RG4733 / Roche
NCT01154452: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Checkmark GDC-0449 in combination with RG4733
Jun 2012 - Jun 2012: GDC-0449 in combination with RG4733
Completed
1b
78
US
Gamma-Secretase Inhibitor RO4929097, RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
02/15
02/15
NCT01269411: RO4929097 in Treating Patients With Recurrent Invasive Gliomas

Terminated
1
22
Canada
gamma-secretase/Notch signalling pathway inhibitor RO4929097, R4733, RO4929097, therapeutic conventional surgery, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
02/12
 
NCT01119599: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Completed
1
22
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Gamma-Secretase Inhibitor RO4929097, RO4929097, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temodal, Temodar, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Primary Melanocytic Lesion of Meninges, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma
06/13
 
NCT01131234: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Checkmark ro4929097 and cediranib in patients with advanced solid tumours
Jul 2013 - Jul 2013: ro4929097 and cediranib in patients with advanced solid tumours
Checkmark P1 data - ESMO
Sep 2012 - Sep 2012: P1 data - ESMO
Completed
1
20
Canada
Gamma-Secretase Inhibitor RO4929097, RO4929097, Cediranib Maleate, AZD2171, Recentin, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Solid Neoplasm, Male Breast Carcinoma, Recurrent Adult Brain Neoplasm, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Melanoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Carcinoma, Recurrent Rectal Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Breast Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Breast Cancer, Stage IIIC Colon Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
09/14
09/14

Download Options